The global 3D printed drugs market size was estimated to be USD 95.8 million in 2023 and is expected to reach at USD 460.0 million by 2034 with a CAGR of 15.33% during the forecast period 2024-2034. The increasing request for tailor-made medications, the rapid expansion of research and development endeavors supporting 3D printing, a rise in chronic disease cases, an escalating requirement for cost-effective pharmaceuticals or tablets, the expanding utility of 3D printing in the healthcare industry, augmented investments by industry participants in the manufacturing of advanced and efficient 3D printed pharmaceuticals, continual advancements in 3D printing technology, and an increasing launch of drugs produced through 3D printing are some of the key factors boosting the market growth.
An increasing launch of drugs produced through 3D printing is predicted to boost the market growth during the forecast period. Prescriptions for 3D printed drugs involve the use of the 3D printing method to produce personalized medications that are both safe and efficient. These drugs possess a unified porous structure, ensuring easy dispersal in the mouth and eliminating the necessity to ingest high-dose medications in their entirety. This method enables manufacturers to easily customize the size, appearance, shape, and rate of release for a diverse array of drugs. For instance, in June 2023, TRIASTEK has announced the successful conclusion of the first-in-human (FIH) study for its third 3D printed drug, T21, intended for the treatment of mild to severe ulcerative colitis (UC). T21 is specifically formulated to deliver the drug directly to the colon, utilizing TRIASTEK's 3D Microstructure for Colon Targeting. This marks the first human verification for the company in this context.
By technology, zip dose technology was the highest revenue-grossing segment in the global 3D printed drugs market in 2023 owing to its user-friendly nature, rising adoption of this technology particularly among patients with dysphagia, an escalating demand especially among geriatric & pediatric patients for swiftly soluble drugs that disperse rapidly in the mouth, and growing trend of partnerships & collaborations among market players. For instance, in November 2023, Aprecia, a precision drug delivery company, has collaborated with research and development specialists at Battelle to create an innovative 3D printing platform named Z-FORM. This platform has the potential to revolutionize the entire process of medicine development, production, distribution, and administration. Similar to its transformative impact on various industries, 3D printing technology is now positioned to bring about significant changes in the pharmaceutical manufacturing sector. Additionally, inkjet printer is predicted to grow at the fastest CAGR during the forecast period owing to the growing occurrence of epilepsy cases, persistent advancements in 3D printing technology, and an increasing recognition of this technology. This method produces 3D drugs consistently and possesses technological advantages over alternative techniques, leading to a high level of acceptance among patients. Inkjet printing involves depositing three-dimensional shapes in solid dosage forms by ejecting different combinations of active pharmaceutical ingredients and excipients (inks) through a nozzle.
By application, neurology was the highest revenue-grossing segment in the global 3D printed drugs market in 2023 owing to the increasing investment by pharmaceutical companies, regulatory bodies are granting more approvals, and a rise in the incidence of diverse neurological disorders, including Parkinson's disease. For instance, in April 2022, In a published article, scientists from Germany and the Netherlands employed 3D printing technology to produce a Mini-Floating-Polypill as a treatment for Parkinson's disease. The study utilized fused deposition modeling (FDM). Additionally, orthopedic is predicted to grow at the fastest CAGR during the forecast period. Orthopedic procedures are intricate and challenging, requiring innovative approaches to address various recognized challenges and enhance patient outcomes. Complications, particularly the elevated risk of infection, often lead to prolonged patient discomfort and functional impairment. Therefore, the utilization of orthopedic drugs to counteract postoperative infections is driving the growth of the market.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global 3D printed drugs market in 2023 owing to the extensive utilization of prescription medications for managing various chronic conditions, the increasing need for pharmaceuticals, and the cost-efficient application of bio-drugs through this technology are on the rise. This approach has the potential to significantly reduce costs, minimize waste, and alleviate environmental pressure. Additionally, research laboratories is predicted to grow at the fastest CAGR during the forecast period owing to the increase in research and development efforts focused on 3D printed drugs, accompanied by a rise in collaborations among industry leaders. For instance, in March 2023, Hovione and Laxxon Medical have entered into a strategic partnership to enhance the utilization of 3D screen printing technologies within the pharmaceutical sector. This collaboration integrates Laxxon's proficiency in 3D screen printing, utilizing their SPID-Technology, with Hovione's capabilities in product and process development, engineering, and pharmaceutical manufacturing. According to the agreement, Hovione will implement Laxxon Medical's 3D screen printing technology initially at Hovione's cGMP production facilities in Portugal, followed by deployment in the USA at a later stage.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of chronic diseases, significant investment in research and development, increased utilization of technological advancements, and an increasing introduction of novel products. For instance, in October 2023, CurifyLabs, a health technology company based in Finland, has introduced what it claims to be the world's first GMP (good manufacturing practice) manufactured Pharma Inks designed for 3D printable medications. According to CurifyLabs, this offers an innovative solution for creating customized and personalized medicines within pharmacies and hospitals. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the increase in substantial advancements in the technological incorporation of 3D printed drug approaches, the enhancement of healthcare infrastructure, an uptick in research and development initiatives, and an escalation in investments within the 3D printing sector. For instance, in March 2022, Evonik Venture Capital has made an investment in Laxxon Medical, a company located in Nevada, to support the production of 3D-printed tablets. Laxxon Medical has created a 3D screen-printing technology for manufacturing structured tablets that enable the controlled release of active pharmaceutical ingredients (API) over a specific period.
An increasing launch of drugs produced through 3D printing is predicted to boost the market growth during the forecast period. Prescriptions for 3D printed drugs involve the use of the 3D printing method to produce personalized medications that are both safe and efficient. These drugs possess a unified porous structure, ensuring easy dispersal in the mouth and eliminating the necessity to ingest high-dose medications in their entirety. This method enables manufacturers to easily customize the size, appearance, shape, and rate of release for a diverse array of drugs. For instance, in June 2023, TRIASTEK has announced the successful conclusion of the first-in-human (FIH) study for its third 3D printed drug, T21, intended for the treatment of mild to severe ulcerative colitis (UC). T21 is specifically formulated to deliver the drug directly to the colon, utilizing TRIASTEK's 3D Microstructure for Colon Targeting. This marks the first human verification for the company in this context.
By technology, zip dose technology was the highest revenue-grossing segment in the global 3D printed drugs market in 2023 owing to its user-friendly nature, rising adoption of this technology particularly among patients with dysphagia, an escalating demand especially among geriatric & pediatric patients for swiftly soluble drugs that disperse rapidly in the mouth, and growing trend of partnerships & collaborations among market players. For instance, in November 2023, Aprecia, a precision drug delivery company, has collaborated with research and development specialists at Battelle to create an innovative 3D printing platform named Z-FORM. This platform has the potential to revolutionize the entire process of medicine development, production, distribution, and administration. Similar to its transformative impact on various industries, 3D printing technology is now positioned to bring about significant changes in the pharmaceutical manufacturing sector. Additionally, inkjet printer is predicted to grow at the fastest CAGR during the forecast period owing to the growing occurrence of epilepsy cases, persistent advancements in 3D printing technology, and an increasing recognition of this technology. This method produces 3D drugs consistently and possesses technological advantages over alternative techniques, leading to a high level of acceptance among patients. Inkjet printing involves depositing three-dimensional shapes in solid dosage forms by ejecting different combinations of active pharmaceutical ingredients and excipients (inks) through a nozzle.
By application, neurology was the highest revenue-grossing segment in the global 3D printed drugs market in 2023 owing to the increasing investment by pharmaceutical companies, regulatory bodies are granting more approvals, and a rise in the incidence of diverse neurological disorders, including Parkinson's disease. For instance, in April 2022, In a published article, scientists from Germany and the Netherlands employed 3D printing technology to produce a Mini-Floating-Polypill as a treatment for Parkinson's disease. The study utilized fused deposition modeling (FDM). Additionally, orthopedic is predicted to grow at the fastest CAGR during the forecast period. Orthopedic procedures are intricate and challenging, requiring innovative approaches to address various recognized challenges and enhance patient outcomes. Complications, particularly the elevated risk of infection, often lead to prolonged patient discomfort and functional impairment. Therefore, the utilization of orthopedic drugs to counteract postoperative infections is driving the growth of the market.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global 3D printed drugs market in 2023 owing to the extensive utilization of prescription medications for managing various chronic conditions, the increasing need for pharmaceuticals, and the cost-efficient application of bio-drugs through this technology are on the rise. This approach has the potential to significantly reduce costs, minimize waste, and alleviate environmental pressure. Additionally, research laboratories is predicted to grow at the fastest CAGR during the forecast period owing to the increase in research and development efforts focused on 3D printed drugs, accompanied by a rise in collaborations among industry leaders. For instance, in March 2023, Hovione and Laxxon Medical have entered into a strategic partnership to enhance the utilization of 3D screen printing technologies within the pharmaceutical sector. This collaboration integrates Laxxon's proficiency in 3D screen printing, utilizing their SPID-Technology, with Hovione's capabilities in product and process development, engineering, and pharmaceutical manufacturing. According to the agreement, Hovione will implement Laxxon Medical's 3D screen printing technology initially at Hovione's cGMP production facilities in Portugal, followed by deployment in the USA at a later stage.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of chronic diseases, significant investment in research and development, increased utilization of technological advancements, and an increasing introduction of novel products. For instance, in October 2023, CurifyLabs, a health technology company based in Finland, has introduced what it claims to be the world's first GMP (good manufacturing practice) manufactured Pharma Inks designed for 3D printable medications. According to CurifyLabs, this offers an innovative solution for creating customized and personalized medicines within pharmacies and hospitals. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the increase in substantial advancements in the technological incorporation of 3D printed drug approaches, the enhancement of healthcare infrastructure, an uptick in research and development initiatives, and an escalation in investments within the 3D printing sector. For instance, in March 2022, Evonik Venture Capital has made an investment in Laxxon Medical, a company located in Nevada, to support the production of 3D-printed tablets. Laxxon Medical has created a 3D screen-printing technology for manufacturing structured tablets that enable the controlled release of active pharmaceutical ingredients (API) over a specific period.
Segmentation: 3D Printed Drugs Market Report 2023 - 2034
3D Printed Drugs Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Mn)
- Fused Deposition Modeling
- ZipDose Technology
- Stereolithography
- Inkjet Printing
3D Printed Drugs Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Mn)
- Dental
- Neurology
- Orthopedic
- Others
3D Printed Drugs Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Mn)
- Research Laboratories
- Hospitals & Clinics
- Others
3D Printed Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. 3D Printed Drugs Market: Technology Estimates & Trend Analysis
8. 3D Printed Drugs Market: Application Estimates & Trend Analysis
9. 3D Printed Drugs Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America 3D Printed Drugs Market
12. Europe Global 3D Printed Drugs Market
13. Asia Pacific Global 3D Printed Drugs Market
14. Latin America Global 3D Printed Drugs Market
15. MEA Global 3D Printed Drugs Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Osmotica Pharmaceuticals
- Merck
- Extend Biosciences
- Affinity Therapeutics
- GlaxoSmithKline Plc
- AstraZeneca
- Bioduro
- Hewlett Packard Caribe
- Cycle Pharmaceuticals
- FabRx Ltd
- Aprecia Pharmaceuticals LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 95.8 Million |
| Forecasted Market Value ( USD | $ 459.9 Million |
| Compound Annual Growth Rate | 15.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
